SELVITA S.A. SER.B ZY-80
Research SELVITA S.A. SER.B ZY-80 (787) on Bullrun: market cap EUR 104.97M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker787
- ExchangeF
- CountryPoland
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyEUR
- Market capEUR 104.97M
- Financial periodQ1 2026
- RevenueEUR 75.83M
- Net income-EUR 5.45M
- Free cash flowEUR 5.24M
- Gross margin78.1%
Valuation Snapshot
latest market cap is EUR 104.97M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 364.25M | EUR 813.00K | EUR 66.10M | 80.6% | n/a | EUR 24.22M | EUR 169.57M | EUR 321.73M |
| FY2022 | PLN 407.46M | PLN 32.61M | n/a | n/a | 1.7 | PLN 74.16M | PLN 125.85M | PLN 262.18M |
| FY2021 | PLN 310.92M | PLN 18.22M | n/a | n/a | 0.8 | PLN 83.55M | PLN 92.19M | PLN 196.87M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-07-29 | EUR 104.97M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About SELVITA S.A. SER.B ZY-80
Selvita S.A. provides drug discovery, drug development, and contract testing services in Poland. The company offers computer-aided drug design and artificial intelligence solutions, including structure-based drug design, virtual screening, and bioinformatics; medicinal and synthetic, analytical, and solid state chemistry, as well as process chemistry and scale up, and compound management and libraries; structural biology, fragment-based drug discovery, protein production, modification, and characterization;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is SELVITA S.A. SER.B ZY-80's market cap?
SELVITA S.A. SER.B ZY-80's market capitalization is EUR 104.97M.
What does SELVITA S.A. SER.B ZY-80 do?
Selvita S.A. provides drug discovery, drug development, and contract testing services in Poland. The company offers computer-aided drug design and artificial intelligence solutions, including structure-based drug design, virtual screening, and bioinformatics; medicinal and synthetic, analytical, and solid state chemistry, as well as process chemistry and scale up, and compound management and libraries; structural biology, fragment-based drug discovery, protein production, modification, and characterization; vitro assays and model, mechanistic and target-focused profiling, vitro safety.